Studies on anti-inflammatory agents. V. Synthesis and pharmacological properties of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4- (methylsulfinyl)phenyl]pyrazole and related compounds

Chemical and Pharmaceutical Bulletin

Volumn 45, Issue 9, 1997, Pages 1475-1481

  Tsuji, Kiyoshi ^a   Konishi, Nobukiyo ^a   Spears, Glen W ^a   Ogino, Takashi ^a   Nakamura, Katsuya ^a   Tojo, Takashi ^a   Ochi, Takehiro ^a   Shimojo, Fumio ^a   Senoh, Hachiro ^a   Matsuo, Masaaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

1,5 diphenylpyrazole; Analgesic activity; Anti inflammatory agent; Morphine; Structure activity relationship

Indexed keywords

3 (DIFLUOROMETHYL) 1 (4 METHOXYPHENYL) 5 [4 (METHYLSULFINYL)PHENYL]PYRAZOLE; ADJUVANT; ANTIINFLAMMATORY AGENT; CARRAGEENAN; MORPHINE; PROSTAGLANDIN E2; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; EDEMA; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0030955273     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.45.1475     Document Type: Article

References (42)

1. Part IV: Tsuji K., Nakamura K., Konishi N., Tojo T., Ochi T., Senoh H., Matsuo M., Chem. Pharm. Bull., 45, 987-995 (1997).
2. a) Ivey K. J., Am. J. Med., 75 (5A), 53-64 (1983);
3. b) Nanra R. S., ibid., 75 (5A), 70-81 (1983);
4. c) Allison M. C., Howatson A. G., Torrance C. J., Lee F. D., Russell R. I., N. Eng. J. Med., 327, 749-754 (1992);
5. Laufer S. A., Augastin J., Dannhardt G., Kiefer W., J. Med. Chem., 37, 1894-1897 (1994).
6. a) Reitz A. B., Jetter M. C., Wild K. D., Raffa R. B., Annu. Rep. Med. Chem., 30, 11-20 (1995);
7. b) Piaz V. D., Giovannoni M. P., Ciciani G., Barlocco D., Giardina G., Petrone G., Clarke G. D., Eur. J. Med. Chem., 31, 65-70 (1996);
8. c) Flouzat C., Bresson Y., Mattio A., Bonnet J., Guillaumet G., J. Med. Chem., 36, 497-503 (1993).
9. Matsuo M., Tsuji K., Konishi N., Nakamura K., Eur. Patent 418845 (1991) [Chem. Abstr., 115, 71593z (1991)].
10. Matsuo M., Tsuji K., Konishi N., Nakamura K., Eur. Patent 418845 (1991) [Chem. Abstr., 115, 71593z (1991)].
11. Ochi T., Jobo K., Orito K., Fujii T., Jpn. J. Pharmacol., 71 (Suppl. 1), 212 (1996).
12. a) Isakson P., Seibert K., Masferrer J., Salvemini D., Lee L., Needleman P., The 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 1994;
13. b) Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P., Proc. Natl. Acad. Sci. U.S.A., 91, 12013-12017 (1994).
14. Tsuji K., Nakamura K., Konishi N., Okumura H., Matsuo M., Chem. Pharm. Bull., 40, 2399-2409 (1992).
15. a) Ariëns E. J., Trends Pharmacol. Sci., 14, 68-75 (1993);
16. b) Shindou H., Pharm. Tech. Japan, 5(10), 1-8 (1989);
17. c) Hayball P. J., Drugs, 52 (Suppl. 5), 47-58 (1996).
18. a) Zhao S. H., Samuel O., Kagan H. B., Org. Synth., 68, 49-55 (1990);
19. b) Furia F. D., Modena G., Seraglia R., Synthesis, 1984, 325-326;
20. c) Davis F. A., Reddy R. T., Han W., Carroll P. J., J. Am. Chem. Soc., 114, 1428-1437 (1992);
21. d) May S. W., Phillips R. S., ibid., 102, 5981-5983 (1980).
22. a) Marino J. P., Bogdan S., Kimura K., J. Am. Chem. Soc., 114, 5566-5572 (1992);
23. b) Whitesell J. K., Wong M. S., J. Org. Chem., 56, 4552-4554 (1991).
24. R of 27, 8.1 min).
25. a) Sharpe T. R., Cherkofsky S. C., Hewes W. E., Smith D. H., Gregory W. A., Haber S. B., Leadbetter M. R., Whitney J. G., J. Med. Chem., 28, 1188-1194 (1985);
26. b) Lombardino J. G., Wiseman E. H., ibid., 17, 1182-1188 (1974);
27. c) Haber S. B., Eur. Patent 55470 (1982) [Chem. Abstr., 97, 198099h (1982)];
28. c) Haber S. B., Eur. Patent 55470 (1982) [Chem. Abstr., 97, 198099h (1982)];
29. d) Idem, Eur. Patent 55471 (1982) [Chem. Abstr., 97, 198098g (1982)];
30. d) Idem, Eur. Patent 55471 (1982) [Chem. Abstr., 97, 198098g (1982)];
31. e) Cherkofsky S. C., U. S. Patent 4302461 (1981) [Chem. Abstr., 96, 104081a (1982)].
32. e) Cherkofsky S. C., U. S. Patent 4302461 (1981) [Chem. Abstr., 96, 104081a (1982)].
33. 50 = 0.035 μM), but it was inactive toward normal paw in the Randall-Selitto assay at 10 mg kg, and in the tail-pinch assay at 320 mg/kg.
34. Compound 10 (80 mg/kg p.o.) and morphine (40 mg/kg p.o.) were inactive when naloxone (0.2 mg/kg s.c.) was administered simultaneously in the tail-pinch assay (T. Ochi et al., unpublished results).
35. Assayed using Novascreen® (n = 2).
36. Unpublished results of the Analytical Research Laboratories.
37. This product was used for the next step without further purification.
38. Nakamura K., Tsuji K., Konishi N., Okumura H., Matsuo M., Chem. Pharm. Bull., 41, 894-906 (1993).
39. Nakamura K., Tsuji K., Konishi N., Matsuo M., Chem. Pharm. Bull., 41, 2050-2052 (1993).
40. Takagi H., Inukai T., Nakama M., Jpn. J. Pharmacol., 16, 287-294 (1966).
41. Matsuo M., Tsuji K., Konishi N., Nakamura K., PCT Int. Appl. WO 91 19708 (1991) [Chem. Abstr., 116, 194141d (1992)].
42. Matsuo M., Tsuji K., Konishi N., Nakamura K., PCT Int. Appl. WO 91 19708 (1991) [Chem. Abstr., 116, 194141d (1992)].